Evidence map›Paper›PMID 31805710›Full record

ArticleCancers2019

Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer.

Yen-Liang Liu, Aaron M Horning, Brandon Lieberman, Mirae Kim, Che-Kuang Lin, Chia-Nung Hung, Chih-Wei Chou, Chiou-Miin Wang, Chun-Lin Lin, Nameer B Kirma and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent Advances in Single-Molecule Tracking and Imaging Techniques.Annual review of analytical chemistry (Palo Alto, Calif.) · 2023
    Review
  4. Article
  5. The Roles of EphB2 in Cancer.Frontiers in cell and developmental biology · 2022
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Yen-Liang LiuGraduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
Aaron M HorningDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Brandon LiebermanDepartment of Biology, Trinity University, San Antonio, TX 78212, USA.
Mirae KimDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Che-Kuang LinDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Chia-Nung HungDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Chih-Wei ChouDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Chiou-Miin WangDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Chun-Lin LinDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Nameer B KirmaDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Michael A LissDepartment of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Rohan VasishtDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Evan P PerilloDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Katherine BlocherDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Hannah HorngDepartment of Bioengineering, the University of Maryland, College Park, MD 20742, USA.
Josephine A TavernaDepartment of Medicine, Mays Cancer Center, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Jianhua RuanDepartment of Computer Science, University of Texas at San Antonio, TX 78249, USA.
Thomas E YankeelovDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Andrew K DunnDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Tim H-M HuangDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
Hsin-Chih YehDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton, BME Building, Austin, TX 78712, USA.
Chun-Liang ChenDepartment of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center, 8210 Floyd Curl Drive, Mail code: 8257 , San Antonio, TX 78229, USA.
The University of Texas Health Science Center at San Antonio · USThe University of Texas at Austin · USChina Medical University · TWLivestrong Foundation · USThe University of Texas at San Antonio · USTrinity University · USUniversity of Maryland, College Park · US

Funding

Institutional Career Development Core (KL2)KL2TR002646 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI TSEVAT, JOEL · 2018 to 2022
$3.4M
Cancer Biology Training ProgramT32CA148724 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Pei Wang, Feng-Chun Yang · 2011 to 2026
$3.3M
An integrated imaging tool for probing EGFR subcellular trafficking in real timeR21CA193038 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI DUNN, ANDREW K, YEH, HSIN-CHIH · 2015 to 2017
$625k
Cancer Prevention and Research Institute of Texas RP150600Cancer Prevention and Research Institute of Texas RR160005National Institutes of Health (USA) CA193038National Institutes of Health (USA) P30CA054174National Institutes of Health (USA) T32CA148724National Institutes of Health (USA) U54CA217297NCATS NIH HHS KL2 TR002646NCI NIH HHS R21 CA193038NCI NIH HHS T32 CA148724Robert A. Welch Foundation F-1833
6 · The paper itself

Abstract

Advanced prostate cancer is a very heterogeneous disease reflecting in diverse regulations of oncogenic signaling pathways. Aberrant spatial dynamics of epidermal growth factor receptor (EGFR) promote their dimerization and clustering, leading to constitutive activation in oncogenesis. The EphB2 and Src signaling pathways are associated with the reorganization of the cytoskeleton leading to malignancy, but their roles in regulating EGFR dynamics and activation are scarcely reported. Using single-particle tracking techniques, we found that highly phosphorylated EGFR in the advanced prostate cancer cell line, PC3, was associated with higher EGFR diffusivity, as compared with LNCaP and less aggressive DU145. The increased EGFR activation and biophysical dynamics were consistent with high proliferation, migration, and invasion. After performing single-cell RNA-seq on prostate cancer cell lines and circulating tumor cells from patients, we identified that upregulated gene expression in the EphB2 and Src pathways are associated with advanced malignancy. After dasatinib treatment or siRNA knockdowns of EphB2 or Src, the PC3 cells exhibited significantly lower EGFR dynamics, cell motility, and invasion. Partial inhibitory effects were also found in DU145 cells. The upregulation of parts of the EphB2 and Src pathways also predicts poor prognosis in the prostate cancer patient cohort of The Cancer Genome Atlas. Our results provide evidence that overexpression of the EphB2 and Src signaling pathways regulate EGFR dynamics and cellular aggressiveness in some advanced prostate cancer cells.

Indexed as

actincompartmentalizationdiffusivityEGFRendocytosisEphB2epithelial–mesenchymal transitionmetastasisprostate cancersingle-particle trackingSrc

Identifiers

PMID31805710
PMCPMC6966510
OpenAlexW2990577177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.